3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

Want some quality dividend stocks to buy, but don't want to break the bank? The stocks listed below offer above-average yields and trade at less than $100. They are an attractive option for investors seeking a balance of high yields and modest valuations.

Novo Nordisk (NYSE:NVO), CVS Health (NYSE:CVS), and Bristol Myers Squibb (NYSE:BMY)are all big names in healthcare. And for income-seeking investors, they can also make for excellent dividend stocks to buy right now. Here’s why.

Image source: Getty Images.

Novo Nordisk

Healthcare giant Novo Nordisk has been struggling due to rising competition, and its shares are down 17% over the past year. It's been struggling to keep up with its key rival, Eli Lilly, and investors have been dumping the stock as its growth rate has been underwhelming of late.

However, the good news is that Novo Nordisk still has growth opportunities to tap into. It owns the popular GLP-1 drugs Wegovy and Ozempic and is developing additional medications. In the healthcare sector, the excitement often centers on new developments. Unfortunately, Novo Nordisk has been lagging in that area, but it still has many projects ongoing within its pipeline.

Plus, a higher-dose version of semaglutide, the active ingredient in Wegovy and Ozempic, has been associated with significantly greater weight loss, which could intensify competition with Eli Lilly in the future.

Novo Nordisk is a bit underrated right now, but with the stock trading at just 11 times its trailing earnings and offering a 4% dividend yield, it could be a great buy. The stock closed at just under $45 on Monday.

CVS Health

Another healthcare stock that looks like a solid value buy these days is CVS Health, which is known for its pharmacies across the country. However, it also has a massive healthcare business, having acquired Aetna in 2018. The overall business is now massive, with CVS generating $415 billion in revenue over the past four quarters.

The stock has been rallying this year as CVS's results have improved and its costs have proven more manageable. Since the start of 2026, shares of the healthcare giant have risen by 18%. It closed just over $94 yesterday as it approaches the $100 mark, but isn't quite there yet. Despite its impressive gains this year, the stock's valuation remains fairly modest, trading at 13 times its estimated future earnings based on analyst expectations.

At 2.8%, CVS offers an attractive yield, and while it is not as high as Novo Nordisk's, it's still far higher than the S&P 500 average of just over 1%.

Bristol Myers Squibb

The third healthcare stock on this list is pharma giant Bristol Myers Squibb. While it has struggled to win over investors in recent years, it has been rallying this year, especially amid rumors of a potential merger with AstraZeneca. Talks, however, are preliminary, and a deal is by no means a guarantee of going through.

Year to date, the stock is up around 20%, largely due to the recent merger rumors. It's currently trading at around $65 and recently hit a new 52-week high of over $68. But at a forward price-to-earnings multiple of just nine, this is another deeply discounted stock that investors can buy right now. The concern is how the company will navigate patent cliffs and what its future growth will look like. It has, however, been investing in new drugs, and its growth portfolio grew by 15% in its most recent quarter. The overall business generated $13 billion in revenue, up a more modest 6%.

There is some risk with Bristol Myers, but the low valuation gives investors a bit of a margin of safety. It can be a highly attractive option for dividend investors, as the stock currently yields 3.9%.

David Jagielski, CPA has positions in Novo Nordisk. The Motley Fool has positions in and recommends AstraZeneca Plc, Bristol Myers Squibb, Eli Lilly, and Novo Nordisk. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.